Trans-Tasman chooses pharma for first investment
This article was originally published in Scrip
A new joint Australia/New Zealand fund to support the commercialisation of intellectual property deriving from academic research has made its first investment, in an oncology therapeutics venture.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.